A new partnership between Novo Nordisk and OpenAI underscores pharma’s urgency to harness AI for quicker cures.
A recent Pfizer warning shows that regulators are leaning into policing Facebook ads as closely as TV commercials.
Younger consumers respond to GLP-1 ads, but increasing ad spend risks fatigue, making sharper creative and more point-of-care marketing increasingly important.
They start health condition and treatment queries via search engines most often, but rely on journals to verify information, revealing a gap between use and credibility.
GenAI health users will jump 37% YoY in 2026, but most queries will still begin on search—forcing marketers to balance SEO with AI discovery.
Health and beauty ad spending jumps 50%+, while electronics swing with demand cycles, according to our industry KPI data.
Future doctors will likely prescribe nutrition alongside drugs, but without insurer funding, prescribed meals will have limited impact.
HRT prescriptions climb as risk fears ease and patients, doctors, and culture rethink menopause care.
Only 7% of consumers rate social health information as highly accurate, raising the stakes for healthcare and pharma marketing content credibility.
Backlash over Medvi’s telehealth business after a NYT report signals increasing scrutiny of online health ads.
Pharmacies and telehealth brands are racing to capture GLP-1 pill users, making strong customer service and patient support essential.
Rapid share gains in India come at the expense of branded drugs, challenging premium pricing models and raising the bar for new entrants.
Consumer usage is widespread, but their shaky brand trust and safety skepticism makes physician backing critical.
Rising AI adoption among younger consumers for mental health and emotional support makes safe chatbot design table stakes, especially as lawsuits mount.
Mega rounds now dominate late-stage digital health dealmaking, with startups attracting capital through scale, proven market fit, and AI value.
The FDA's 2027 budget would define specific misbranding violations in law, potentially speeding enforcement and raising compliance risks.
73% of US adults miss routine tests as cost fears and confusion over bills stall action.
Consumers may be drawn to unregulated peptide products for now, but long-term brand success in this space will depend on transparency and clear education.
Wellness culture drives increased consumer health spending, but brands still must avoid shame-based messaging that undermines trust.
New drug tariffs of up to 100% spare Big Pharma dealmakers, but force midsize and smaller companies to weigh the steep levies versus compliance costs.